Deucrava 6-MG Tablet
Made in:
Brand:
Capacity:
Indications Deucrava is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucrava is not recommended for […]
Indications
Dosage & Administration
Recommended Dosage: The recommended dosage of Deucravacitinib is 6 mg taken orally once daily, with or without food. Do not crush, cut, or chew the tablets.
Pediatric Use: The safety and effectiveness in pediatric patients have not been established.
Geriatric Use: No overall differences in effectiveness have been observed between patients 65 years of age and older and younger adult patients.
Recommended Dosage in Patients with Hepatic Impairment: Deucravacitinib is not recommended in patients with severe hepatic impairment (Child-Pugh C). No dosage adjustment is needed for patients with mild to moderate hepatic impairment.
Renal Impairment: No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Infections: Deucrava may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue this until the infection resolves.
Tuberculosis: Evaluate for TB prior to initiating treatment with Deucrava.
Malignancy: Malignancies including lymphomas were observed in clinical trials with Deucrava.
Laboratory Abnormalities: Periodically evaluate serum triglycerides. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease.
Immunizations: Avoid use with live vaccines.
Potential Risks Related to JAK Inhibition: It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition. Higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with a JAK inhibitor compared to those treated with TNF blockers in rheumatoid arthritis (RA) patients. This is not approved for use in RA.
Rhabdomyolysis and elevated CPK.
Therapeutic Class
Storage Conditions
| Capacity | 10 Tablets ( 1Strips ) |
|---|








Reviews
There are no reviews yet.